Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA ORS® (edaravone) for the Treatment of ALS
- Friday, May 13, 2022, 7:14
- PR Newswire
- Add a comment
RADICAVA ORS provides patients with ALS a flexible administration option that can be taken orally or via feeding tube, without the need for dose adjustment1 RADICAVA ORS offers the same drug and efficacy as the IV formulation1 Comprehensive clinical development program for edaravone in…
About the Author
admin has written 21729 stories on this site.